Pfizer Arthritis Study May Push Pill Into $12 Billion Market

Published November 8, 2010

Pfizer Arthritis Study May Push Pill Into Billion Market
Pfizer Inc.’s experimental pill for rheumatoid arthritis reduced pain and inflammation without unforeseen side effects in a study that may help the company supplant injectable drugs with $ 12 billion in yearly sales.
Read more on BusinessWeek

SciClone Reports Financial Results for the Third Quarter of 2010 and Provides Updated Guidance for the Full Year
FOSTER CITY, CA–(Marketwire – November 8, 2010) – SciClone Pharmaceuticals, Inc. ( NASDAQ : SCLN ) today reported financial results for the third quarter of 2010. As reported on October 12, 2010, product revenues from sales of ZADAXIN® were $ 22.8 million, an increase of 32.5% compared with revenues of $ 17.2 million for the same period last year. For the nine months ended September 30, 2010 …
Read more on Marketwire

Commercial Insight: Multiple Sclerosis – Next Generation Therapies Signal the Start of a New Era
Reportlinker.com announces that a new market research report is available in its catalogue:
Read more on PR Newswire via Yahoo! Finance